Spectranetics touts 100% survival rate in Bridge occlusion balloon study

Spectranetics (NSDQ:SPNC) today released data from a late breaking clinical trial of its Bridge occlusion balloon designed to reduce blood loss due to superior vena cava tears during lead extraction procedures, touting a 100% survival rate amongst patients treated with the balloon. The company presented 1-year clinical experience data from the study today at the Heart Rhythm Society’s 38th Annual Scientific Sessions. The Colorado Springs, Colo.-based company’s Bridge balloon is designed to reduce blood loss in the event of a tear and to provide a “bridge” to surgical intervention. The study aimed to explore the early impact of the balloon on the management of SVC tears as well as survival outcomes for patients treated. “By having a tool that can occlude the bleeding and reduce exsanguination, you have a more stable patient. You also have more time to do a better repair, and therefore have a better outcome,” study investigator Dr. Roger Carrillo of the University of Miami Hospital told MassDevice.com in an interview. In the study, researchers evaluated 35 confirmed SVC tears and 33 non-SVC events, with 9 confirmed SVC patients being treated with the Bridge balloon and 26 without. Of the 9 treated with the balloon, all patients were discharged alive from the hospital. Only 50% of patients with SVC events who were not treated with the balloon survived the procedure, according to the study. “From a clinical point of view, [the Bridge balloo...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Catheters Clinical Trials Spectranetics Corp. Source Type: news